An asthma drug put a hard-to-treat swallowing disease into remission for 7 in 10 patients

Eosinophilic esophagitis makes the food pipe swell until swallowing becomes a daily hazard — food can stick fast. Amgen and AstraZeneca report that their drug Tezspire, already used for severe asthma, put the inflammation into remission in 65–69% of trial patients at 24 weeks, against just 3.5% on placebo — and the benefit held through a full year, with swallowing-difficulty scores improving more than on placebo. The most common side effects were the ordinary kind: colds, headache, diarrhoea. For people who plan meals around fear of choking, a 69% remission rate is not a statistic; it's dinner, back to normal.

SDG 3 · Good health and well-being — Mechanism: tech innovation